These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 23437909)

  • 1. Immediate effects of different schedules of somatostatin on portal pressure in patients with liver cirrhosis.
    Zhang C; Xu JM; Kong DR; Min XK; Chen R
    J Clin Pharm Ther; 2013 Jun; 38(3):206-11. PubMed ID: 23437909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study.
    Berzigotti A; Bellot P; De Gottardi A; Garcia-Pagan JC; Gagnon C; Spénard J; Bosch J
    Am J Gastroenterol; 2010 May; 105(5):1094-101. PubMed ID: 19920806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: a double-blind hemodynamic investigation.
    Cirera I; Feu F; Luca A; García-Pagán JC; Fernández M; Escorsell A; Bosch J; Rodés J
    Hepatology; 1995 Jul; 22(1):106-11. PubMed ID: 7601400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of two different dosages of octreotide on portal pressure and hepatic hemodynamics in cirrhotic portal hypertensive patients after portal-azygous devascularization and splenectomy].
    Lu SC; Meng FK; Ding HG; Zhang JG; Ding L; Wang SZ
    Zhonghua Nei Ke Za Zhi; 2007 Apr; 46(4):290-3. PubMed ID: 17637266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin.
    Bosch J; Kravetz D; Rodes J
    Gastroenterology; 1981 Mar; 80(3):518-25. PubMed ID: 6108897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
    Abraldes JG; Albillos A; Bañares R; Turnes J; González R; García-Pagán JC; Bosch J
    Gastroenterology; 2009 May; 136(5):1651-8. PubMed ID: 19208350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemodynamic effects of continuous versus bolus infusion of terlipressin for portal hypertension: a randomized comparison.
    Ding C; Wu X; Fan X; He C; Li J
    J Gastroenterol Hepatol; 2013 Jul; 28(7):1242-6. PubMed ID: 23489113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of variceal pressure by propranolol: comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis.
    Feu F; Bordas JM; Luca A; García-Pagán JC; Escorsell A; Bosch J; Rodés J
    Hepatology; 1993 Nov; 18(5):1082-9. PubMed ID: 8225212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of somatostatin, terlipressin and somatostatin plus terlipressin on portal and systemic hemodynamics and renal sodium excretion in patients with cirrhosis.
    Kalambokis G; Economou M; Paraskevi K; Konstantinos P; Pappas C; Katsaraki A; Tsianos EV
    J Gastroenterol Hepatol; 2005 Jul; 20(7):1075-81. PubMed ID: 15955217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of somatostatin on splanchnic hemodynamics in liver cirrhosis].
    Merkel C; Gatta A; Zuin R; Finucci GF; Arnaboldi L; Ruol A
    Minerva Med; 1984 Nov; 75(44):2673-8. PubMed ID: 6151151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison.
    Baik SK; Jeong PH; Ji SW; Yoo BS; Kim HS; Lee DK; Kwon SO; Kim YJ; Park JW; Chang SJ; Lee SS
    Am J Gastroenterol; 2005 Mar; 100(3):631-5. PubMed ID: 15743362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodynamic effects of terlipressin and high somatostatin dose during acute variceal bleeding in nonresponders to the usual somatostatin dose.
    Villanueva C; Planella M; Aracil C; López-Balaguer JM; González B; Miñana J; Balanzó J
    Am J Gastroenterol; 2005 Mar; 100(3):624-30. PubMed ID: 15743361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes of hepatic and systemic haemodynamics following somatostatin administration in patients with hepatitis B-related cirrhosis.
    Hsia HC; Lin HC; Lee FY; Tsai YT; Lee SD; Meng HC; Chao Y; Wang SS; Lo KJ
    J Gastroenterol Hepatol; 1993; 8(1):15-20. PubMed ID: 8094983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Octreotide bolus injection and azygos blood flow in patients with cirrhosis: is the effect really predictable?
    Spahr L; Giostra E; Mentha G; Hadengue A
    J Clin Gastroenterol; 2010 Oct; 44(9):e206-9. PubMed ID: 19996986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocity.
    Baik SK; Park DH; Kim MY; Choi YJ; Kim HS; Lee DK; Kwon SO; Kim YJ; Park JW; Chang SJ
    J Gastroenterol; 2003; 38(12):1150-4. PubMed ID: 14714252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of octreotide in patients with cirrhosis and portal hypertension; relationship between the plasma levels of the analogue and the magnitude and duration of the reduction in corrected wedged hepatic venous pressure.
    Jenkins SA; Nott DM; Baxter JN
    HPB Surg; 1998; 11(1):13-21. PubMed ID: 9830576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension.
    Escorsell A; Bandi JC; Andreu V; Moitinho E; García-Pagán JC; Bosch J; Rodés J
    Gastroenterology; 2001 Jan; 120(1):161-9. PubMed ID: 11208725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension.
    Manolakopoulos S; Triantos C; Theodoropoulos J; Vlachogiannakos J; Kougioumtzan A; Papatheodoridis G; Tzourmakliotis D; Karamanolis D; Burroughs AK; Archimandritis A; Raptis S; Avgerinos A
    J Hepatol; 2009 Sep; 51(3):468-74. PubMed ID: 19616339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of somatostatin on splanchnic haemodynamics in patients with liver cirrhosis.
    Eriksson LS; Law DH; Sato Y; Wahren J
    Clin Physiol; 1984 Feb; 4(1):5-11. PubMed ID: 6141861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disagreement between acute and chronic haemodynamic effects of nadolol in cirrhosis: a pathophysiological interpretation.
    Merkel C; Bolognesi M; Sacerdoti D; Bombonato G; Cavasin L; Gatta A
    Aliment Pharmacol Ther; 2005 Sep; 22(5):433-9. PubMed ID: 16128681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.